SAN DIEGO – ResMed revenue for the quarter ended December 31, 2024 increased 10% to $1.3 billion; up 10% on a constant currency basis. Gross margin improved 300 bps to 58.6%; non-GAAP gross margin improved 230 bps to 59.2%
Income from operations increased 52% with non-GAAP income from operations up 19%. Operating cash flow hit $309 million. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS growth were the result of increased demand for our sleep health and breathing health products and digital health solutions that people love, as well as our laser-focus on operational excellence,” said ResMed’s Chairman and CEO Mick Farrell. “We delivered 10% year-over-year revenue growth, 230 bps improvement in gross margin, and $309 million of operating cash flow.
“These results are a continuation of the incredible commitment from our team to create a clear market-leading value proposition in connected digital health,” Farrell continued. “Our ecosystem is unmatched and ResMed is well-positioned to capitalize on the once-in-a-generation opportunities we have with the recent introduction and adoption of consumer wearables that track sleep health, as well as use of GLP-1 therapies. We believe these developments will drive increased patient flow as we continue to educate people on the benefits of healthy sleep and breathing, with care delivered right in their own home.”
